# A Study to Assess Relative Bioavailability of Branebrutinib, From a Tablet Formulation to the Capsule Formulation, the Effect of Food on the Bioavailability of Branebrutinib From a Tablet Formulation, and the Safety and Drug Levels of Branebrutinib From a Tablet Formulation in Healthy Participants

> **NCT05303220** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 56 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Branebrutinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05303220
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-08
- **Primary completion:** 2022-08-18
- **Final completion:** 2022-08-18
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2023-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05303220

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05303220, "A Study to Assess Relative Bioavailability of Branebrutinib, From a Tablet Formulation to the Capsule Formulation, the Effect of Food on the Bioavailability of Branebrutinib From a Tablet Formulation, and the Safety and Drug Levels of Branebrutinib From a Tablet Formulation in Healthy Participants". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05303220. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*